Articles tagged "Induction therapy"

2021 American Transplant Congress
Alemtuzumab vs Antithymocyte Globulin Induction in Hepatitis C Viremic Donors to Hepatis C Negative Kidney Transplant Recipients
K. Walter, L. Mincemoyer, J. Giang, J. Suero, N. Shah, K. Szempruch
University of North Carolina Medical Center, Chapel Hill, NC
*Purpose: The optimal induction agent for kidney transplantation of hepatitis C virus nucleic acid test positive donors to negative recipients (HCV NAT D+/R-) is unknown.…
2021 American Transplant Congress
Sirolimus (srl) versus Everolimus (evr) versus Mycophenolate (mpa) in Kidney Transplant Recipients Receiving Anti-thymocyte Globulin Induction (r-atg), Tacrolimus (tac), and Prednisone
H. Tedesco Silva Junior, C. Felipe, L. Viana, M. Cristelli, N. Tenorio, V. Lima, V. Azevedo, K. Ficher, J. Rezende, R. Foresto, M. Nakamura, Y. Dreige, J. Taddeo, C. Zito, J. Medina
Hospital do Rim, Universidade Federal de São Paulo, São Paulo, Brazil
*Purpose: The aim of this study is to compare the efficacy and safety of SRL versus EVR versus MPA in kidney transplant recipients.*Methods: This is…
2021 American Transplant Congress
Outcomes in Standard vs. Extended Use of Thymoglobulin as Induction Therapy in Kidney Transplant Recipients
N. M. Sifontis¹, A. Coleman¹, D. Tang¹, K. Lau², S. Karhadkar², A. DiCarlo², A. Diamond²
¹Temple University School of Pharmacy, Philadelphia, PA, ²Temple University Health System, Philadelphia, PA
*Purpose: Thymoglobulin induction along with modern maintenance immunosuppression has been found to have a significant reduction in acute rejection in kidney transplantation. The recommended duration…
2021 American Transplant Congress
Outcomes of Second Kidney Transplant After Return to Dialysis by Induction Type in the United States
S. Riad¹, T. Shaker¹, S. Jackson², R. Kandaswamy³
¹Medicine, University of Minnesota, Minneapolis, MN, ²Complex Care Analytics, M-Health Fairview, Minneapolis, MN, ³Surgery, University of Minnesota, Minneapolis, MN
*Purpose: A failed kidney allograft is the 4th leading indication for kidney transplantation. We examined the association of induction use in 2nd kidney transplant recipients…
2021 American Transplant Congress
Preemptive Second Kidney Transplant Outcomes by Induction Type in the United States
S. Riad¹, G. Larrieux², S. Jackson³, R. Kandaswamy²
¹Medicine, University of Minnesota, Minneapolis, MN, ²Surgery, University of Minnesota, Minneapolis, MN, ³Complex Care Analytics, M-Health Fairview, Minneapolis, MN
*Purpose: Failed kidney allograft is the fourth leading indication for kidney transplantation. A significant portion of second kidney transplant recipients undergo preemptive transplantation while on…
2021 American Transplant Congress
The Impact of Fixed-Dose Alemtuzumab in Renal Transplant Recipients According to Weight
S. Mandala¹, N. Khodieva², A. Bigness¹, S. Mohamed², H. Mohammed¹, K. Robichaux², A. Brueckner³, R. Baliga⁴, J. Buggs⁵, A. Kumar¹, L. Bowman³
¹Morsani College of Medicine, University of South Florida, Tampa, FL, ²Honors College, University of South Florida, Tampa, FL, ³Transplant Pharmacy, Tampa General Hospital, Tampa, FL, ⁴Nephrology, Florida Kidney Physicians, Tampa, FL, ⁵Transplant Surgery, Tampa General Hospital, Tampa, FL
*Purpose: Alemtuzumab, a potent anti-CD52 monoclonal antibody is used for induction immunosuppression post-renal transplantation as a fixed 30mg dose regardless of the patient’s weight. The…
2021 American Transplant Congress
Cost Savings Initiative with Idea Body Weight Dosing of Rabbit Anti-thymocyte Globulin (rATG) Induction in an Older Kidney Transplant Population: A Single Center Analysis
C. LaFratte¹, S. Witek¹, D. Sawinski², J. Trofe-Clark², C. Sammons², B. Hardek¹, R. Samudralwar¹, A. Forte¹, S. Lyle¹, J. Rashid¹, G. Malat²
¹Pharmacy, Hospital of Univ of Pennsylvania, Philadelphia, PA, ²Penn Transplant Institute, Hospital of Univ of Pennsylvania, Philadelphia, PA
*Purpose: Optimal dosing schemes for rATG induction are not well defined for older kidney transplant recipients (KTRs), who are at greater risk for adverse events…
2021 American Transplant Congress
Impact of Induction Immunosuppression Selection on Clinical Outcomes in Kidney Transplant Recipients During the COVID-19 Pandemic in New York City
K. Khalil, S. Jonchhe, J. Stern, T. C. Lewis, N. Alnazari, B. Lonze, Z. Stewart Lewis, N. Ali
Transplant Institute, NYU Langone Health, New York, NY
*Purpose: As an early epicenter in the coronavirus pandemic, our center modified induction immunosuppression strategies for transplantation. We sought to determine if changes in induction…
2021 American Transplant Congress
Primary Graft Dysfunction in a Risk-Stratified vs. Routine Induction Protocol in Heart Transplant Recipients
J. S. van Zyl¹, H. Zafar¹, P. M. Nguyen², J. Felius¹, T. Sam³, S. A. Hall³
¹Baylor Scott & White Research Institute, Dallas, TX, ²Texas A&M University College of Medicine Health Science Center, Dallas, TX, ³Baylor Scott & White Health, Dallas, TX
*Purpose: Treatment of left ventricular primary graft dysfunction (PGD-LV) is supportive in nature. We aim to evaluate whether a change in induction protocol from a…
2021 American Transplant Congress
Single-Dose Basiliximab Induction Therapy in Low-Immunologic Risk Kidney Transplant Recipients
A. Hutchins, J. Schoen, J. S. McMullen
Pharmacy, Nebraska Medicine, Omaha, NE
*Purpose: The purpose of this study is to examine the outcomes associated with single-dose basiliximab in low-immunologic risk kidney transplant recipients following a revision to…

1
2
3
…
29
Next Page »